Business
Sotera Health Reports Fourth-Quarter and Full-Year 2021 Results; Provides 2022 Outlook
Q4 2021 net revenues increased 11% to $241 million, compared to Q4 2020Q4 2021 net income of $36 million or $0.13 per diluted share, compared to a net loss of
About this update from Sotera Health Company
[{"type":"text","content":"Q4 2021 net revenues increased 11% to $241 million, compared to Q4 2020Q4 2021 net income of $36 million or $0.13 per diluted share, compared to a net loss of $44 million or $(0.17) per diluted share in Q4 2020Q4 2021 Adjusted EBITDA increased 10% to $125 million, compared to Q4 2020Q4 2021 Adjusted EPS of $0.23 improved by $0.14 per diluted share, compared to Q4 2020Full-year 2021 net revenues increased 14% to $931 million, compared to full-year 2020Full-year 2021 net income of $117 million or $0.41 per diluted share, compared to a net loss of $39 million or $(0.16) per diluted share for full-year 2020Full-year 2021 Adjusted EBITDA increased 15% to $481 million, compared to full-year 2020December 31, 2021 total debt of $1.8 billion, net debt of $1.7 billion, and net leverage ratio further reduced to 3.5xFull-year 2022 outlook revenue and Adjusted EBITDA growth of 7% to 11%Increased investment in capacity expansions across all segments and technologies CLEVELAND, March 01, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2021. Fourth-quarter 2021 net revenues increased 11.3% to $241 million, compared with $217 million in the fourth quarter a year ago. Net income attributable to Sotera Health (“net income”) was $36 million, or $0.13 per diluted share, compared with a net loss of $44 million, or $(0.17) per diluted share in the fourth-quarter 2020. Adjusted EBITDA for the fourth-quarter 2021 increased by 10.3% to $125 million over the prior-year quarter. Fourth-quarter 2021 adjusted earnings per diluted share (“Adjusted EPS”) was $0.23, an increase of $0.14 per diluted share, compared to the fourth-quarter 2020. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. For full-year 2021, net revenues increased 13.9% to $931 million, compared with $818 million for full-year 2020. Full-year 2021 net income was $117 million, or $0.41 per diluted share, compared with a net loss of $39 million, or $(0.16) per diluted share, for full-year 2020. Full-year 2021 Adjusted EBITDA increased 14.6% to $481 million, compared to full-year 2020. Adjusted EPS was $0.88 in 2021, an increase o...